Dobutamine and Esmolol, Opposite Action or Sometimes Synergic Therapeutic Actions

  • R. Muchada
Conference paper


The utilization of exogenous cardiac vasoactive products to stabilize cardiovascular function, to optimize oxygen transportation, and to favor homogeneous cellular perfusion is common in anesthesia [1] and in intensive care medicine [2].


Septic Shock Stroke Volume Positive Inotropic Effect Opposite Action Systolic Time Interval 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Muchada R, Haro D, Lamazou J, et al (1991) Efecto de la dobutamina sobre el transporte y el consumo de oxígeno durante la anestesia general con enflurano. Rev Esp Anestesiol Reanim 38: 376–381PubMedGoogle Scholar
  2. 2.
    Martin C, Saux P, Eon B, et al (1990) Septic shock: a goal direct therapy using volume loading, dobutamine and/or epinephrine. Acta Anaesthesiol Scand 34: 413–417PubMedCrossRefGoogle Scholar
  3. 3.
    Dale HH 1906 On some physiological actions of Ergot. J Physiol 34 163–167Google Scholar
  4. 4.
    Ahlquist RP (1948) A study of the adrenotropic receptors. Am J Physiol 135: 586–597Google Scholar
  5. 5.
    Lekfkowitz RJ (1974) Selectivity in beta — adrenergic responses. Clinical implication. Circulation 49: 783–786CrossRefGoogle Scholar
  6. 6.
    Lechat P (1998) Agonistes B-Adrenargiques (adénaline, dopamine, dobutamine, salbutamol); B-bloquants. Principes et regies d’utilisation. Rev Praticien 48: 1115–1121Google Scholar
  7. 7.
    Lavandier B, Cathignol D, Muchada R (1985) Non invasive aortic blood flow measurement using an intraoesophageal probe. Ultrasound Med Biol 11: 451–460PubMedCrossRefGoogle Scholar
  8. 8.
    Muchada R. (1988) Continuous and non invasive hemodynamic profile monotoring including aortic blood flow, systolic time intervals and PetCO2 masurements. In: Kazuyuki I, Matsuyuki D, Tomiei K (eds) State of the art technology in anesthesia and intensive care. Elsevier, Amsterdam pp 75–85Google Scholar
  9. 9.
    Cariou A, Monchi M, Joly JL, et al (1998) Non invasive cardiac output monitoring by aortic blood flow determination: evaluation of the Sometec Dynemo — 3000 system. Crit Care Med 26: 2066–2072PubMedCrossRefGoogle Scholar
  10. 10.
    Muchada R, Piriz H, Cathignol D, et al (1988) Monitorizacion no invasiva del gasto aórtico y otros parámetras hemodinámicos durante la anestesia con isoflurano y enflurano. Rev Esp Anestesiol Reanim 53: 194–198Google Scholar
  11. 11.
    Leier CV, Unverferth DV (1985) Dobutamine. Ann Intern Med 99: 490–496Google Scholar
  12. 12.
    Tuttle RR, Mills J (1975) Dobutamine: development of a new catecholamine to selectively increase cardiac contractility. Circ Res 36: 185–196.PubMedCrossRefGoogle Scholar
  13. 13.
    Tournadre J P, Muchada R, Lansiaux S, Chassard D (1999) Measurements of systolic time intervals using a transoeophageal pulsed echo Doppler. Br J Anaesth 83: 630–636PubMedCrossRefGoogle Scholar
  14. 14.
    Majerus TC, Dasta JF, Bauman JL, et al (1989) Dobutamine: ten years later. Pharamacotherapy 9: 245–259Google Scholar
  15. 15.
    Guyton AC (1996) Heart muscle. The heart as a pump. In: Guyton AC, Hall JE (eds) Textbook of medical physiology. Saunders, Philadelphia, pp 113–114Google Scholar
  16. 16.
    Shakar SF, Abrham WT, Gilbert EM, et al (1998) Combined oral positive inotropic and B blockers therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol 31: 1336–1340PubMedCrossRefGoogle Scholar
  17. 17.
    Bernardin G, Tiger F, Fouché R, Mattei M (1998) Continuous noninvasive measurement of aortic blood flow in critical ill patients with a new esophageal echo — Doppler system. J. Crit Care 13: 177–183CrossRefGoogle Scholar
  18. 18.
    Fowler MB, Lasser JA, Hopkins GL, et al (1986) Assessment of the B adrenergic receptor pathway on the intact failing human heart: progressive receptor down regulation and subsensi-tivity to agonist reponse. Circulation 74: 191CrossRefGoogle Scholar
  19. 19.
    Koch WJ, Lefkowitz RJ, Rockman HA (2000) Functional consequences of altering myocardial adrenergic receptors signaling. Annu Rev Physiol 62: 237–260PubMedCrossRefGoogle Scholar
  20. 20.
    Ahmed A B, Latimer D, Vuylesteke A (2000) Cardiovascular pharmacology: new drugs and new indications. Curr Opin Anaesthesiol 13: 5–13PubMedCrossRefGoogle Scholar
  21. 21.
    Harada K, Tamura M, Ito T et al (1996) Effects of low dose dobutamine on left ventricle diastolic filling in children. Pediatr Cardiol 17: 220–225PubMedCrossRefGoogle Scholar
  22. 22.
    Little WC, Rassi A, Freeman GL (1987) Comparison of effects of dobutamine and ouabain on left ventricular contraction and relaxation in closed chest dogs. J Clin Invest 80: 613–620PubMedCrossRefGoogle Scholar
  23. 23.
    Freemantle N, Cleland J, Young P, et al (1999) B blockers after myocardial infarction: systematic review and meta regression analysis. BMJ 1730-1737Google Scholar
  24. 24.
    Parker MP, Shelhamer JH, Bacharach SL, et al (1984) Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 100: 483–490PubMedGoogle Scholar
  25. 25.
    Lucas CE. (1994) A new look at dopamine and norepinephrine for hyperdynamicseptic shock. Chest 105: 7–8PubMedCrossRefGoogle Scholar
  26. 26.
    Martin C, Vialet R, Potié F, Thomachot L (1996) Interêt des associations de cathécholamines au cours du choc séptique et leur influence sur le pronostic. Reanim Urg 19: 507–516CrossRefGoogle Scholar
  27. 27.
    Schaer GL. (1996) Norepinephrine plus low-dose dopamine: a beneficial combination. Crit Care Med 26:205CrossRefGoogle Scholar
  28. 28.
    Schaer GLF, Parrillo MP (1985) Norepinephrine alone versus norepinephrine plus low doses dopamine: enhanced renal blood flow with combination pressor therapy. Crit Care Med 13: 492–496PubMedCrossRefGoogle Scholar
  29. 29.
    Groeneveld ABJ, Navita JJP, Thijs LG (1989) Peripheral resistance in septic shock: its relation with outcome. Intensive Care Med 14: 141–147Google Scholar
  30. 30.
    Muchada R (1999) Non invasive hemodynamic diagnositic of hyperkinetic septic shock treated with a B Blocker. Intensive Care Med 25[Suppl 1]: 142Google Scholar
  31. 31.
    Collins J A, Skidmore M A, Melvin D B, et al (1990) Home intravenous dobutamine therapy in patients awaiting heart transplantation. J Heart Transplant 9: 205–208PubMedGoogle Scholar
  32. 32.
    Miller L W (1991) Outpatient dobutamine for refractory congestive heart failure: advantages, techniques and results. J Heart Lung Transplant 10: 482–487PubMedGoogle Scholar
  33. 33.
    Hodgson J McB, Aja M, Sorkin RP (1984) Intermittent ambulatory dobutamine infusion in patients awaiting for cardiac transplantation. Am J Cardiol 53: 375–376PubMedCrossRefGoogle Scholar
  34. 34.
    Liang C, Tuttle RR, Hood W B Jr, et al (1979) Conditioning effects of chronic infusion of dobutamine comparison with exercise training. J Clin Invest 64: 613–619PubMedCrossRefGoogle Scholar
  35. 35.
    Swedelberg K Hjmalrson A, Waagstein F, Wellentin (1979) Prolongation of survival in congestive cardiomyopathy by beta receptor blockade. Lancet I: 1374–1376CrossRefGoogle Scholar
  36. 36.
    Nanas J N, Kontoyannis D A, Alexopoulos G P, et al (2001) Long term intermittent dobutamine infusion combined with oral amiodarone improves the survival of patients with severe congestive heart failure. Chest 119: 1173–1178PubMedCrossRefGoogle Scholar
  37. 37.
    Salvi S (2001) Protecting the myocardium from ischemic injury. A critical role for Alpha 1 adrenoreceptors? Chest 119: 142–149Google Scholar
  38. 38.
    Li K, He H, Li C, et al (1997) Myocardial alpha 1 adrenoreceptors: inotropic effects and physiologic implication. Life Sci 60: 1305–1318PubMedCrossRefGoogle Scholar
  39. 39.
    Vernon DD, Garret JS, Banner W, Dean JM (1992) Hemodynamic effects of dobutamine in an intact animal model. Crit Care Med 20:1322–1329PubMedCrossRefGoogle Scholar
  40. 40.
    Lefkowitz RJ, Rockman HA, Koch WJ (2000) Catecholamines, cardiac beta adrenergic receptors and heart failure. Circulation 101: 1634–1637PubMedCrossRefGoogle Scholar
  41. 41.
    Feldman AM, McTiernan C (1998) New insight into the role of enhanced adrenergic receptor-effector coupling in the heart. Circulation 98: 1783–1789CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2002

Authors and Affiliations

  • R. Muchada
    • 1
  1. 1.Department of Anaesthesia and Intensive CareEugène André HospitalLyonFrance

Personalised recommendations